Snapshot img

Colorectal Cancer Therapeutics Market Size 2024-2028

The colorectal cancer therapeutics market size is forecast to increase by USD 2 billion at a CAGR of 4.5% between 2023 and 2028.

The market is experiencing significant growth due to several key factors. The increasing geriatric population, with an accompanying rise in colorectal cancer cases, is a major driver for market expansion. Additionally, the development of small molecule kinase inhibitors is revolutionizing treatment approaches and providing new opportunities for market growth.
Furthermore, the patent expiration of novel therapeutics is leading to increased competition and price erosion, but also fostering innovation and the introduction of more affordable treatment options. These trends and challenges are shaping the future of the market, offering both opportunities and challenges for market participants.

What will be the Size of the Market During the Forecast Period?

Request Free Sample

Colorectal cancer, also known as colon or rectal cancer, is a significant health concern worldwide. According to the American Cancer Society, colorectal adenocarcinoma accounts for the majority of colorectal cancer cases. Gastrointestinal carcinoid tumors are less common but can also contribute to this disease's burden. The market is witnessing substantial growth due to the increasing incident cases and advancements in treatment modalities. Dana-Farber Cancer Institute reports that young-onset colorectal cancer cases have been rising, highlighting the need for more effective therapies. Targeted therapies and immunotherapies are emerging as promising treatment options for colorectal cancer. Avastin (bevacizumab) and Erbitux (cetuximab) are monoclonal antibodies that have shown efficacy in colorectal cancer treatment by inhibiting angiogenesis and EGFR signaling, respectively. Stivarga (regorafenib) is another multi-kinase inhibitor that targets various tyrosine kinases and has been approved for the treatment of metastatic colorectal cancer. Hospital pharmacies, retail pharmacies, and online pharmacies play crucial roles in the distribution of these therapies. The aging population's increasing prevalence and the need for personalized treatment plans have led to a surge in mutation testing for colorectal cancer.
Additionally, diagnosis rates continue to rise due to early detection initiatives and advancements in diagnostic technologies. Key oncology analysts, such as Thomas Wales from MSD, predict that the patent expiries of major colorectal cancer drugs, like Avastin and Erbitux, will lead to increased competition in the market. Genentech's Keytruda (pembrolizumab) and Tecentriq (atezolizumab) are among the immunotherapies gaining popularity due to their potential to offer long-term benefits for certain patient populations. In conclusion, the market is witnessing significant growth due to the rising incident cases, aging population, and advancements in targeted therapies and immunotherapies. The distribution landscape is evolving, with hospital pharmacies, retail pharmacies, and online pharmacies playing essential roles. The market dynamics are complex, with patent expiries and emerging competitors influencing the competitive landscape.

How is this market segmented and which is the largest segment?

The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

Type

  Targeted therapy
  Immunotherapy
  Chemotherapy


Geography

  North America

    Canada
    US


  Europe

    Germany
    UK


  Asia

    China


  Rest of World (ROW)

By Type Insights

The targeted therapy segment is estimated to witness significant growth during the forecast period.

Colorectal cancer (CRC) is a leading cause of cancer-related deaths worldwide. Targeted therapies, which inhibit cancer-causing genes, proteins, or receptors, have emerged as an effective treatment option for CRC. Some targeted therapies used in CRC treatment include bevacizumab (Avastin), regorafenib (Stivarga), ziv-aflibercept (Zaltrap), ramucirumab (cyramza), cetuximab (ERBITUX), and panitumumab (Vectibix). Regorafenib, in particular, is an anti-angiogenic agent that has shown success in treating CRC with the BRAF V600E mutation through its BRAFTOVI form. Hospital, retail, and online pharmacies distribute these therapeutics. Pipeline analysis indicates ongoing research and development for new CRC therapeutics. The regulatory scenario is favorable for the market's growth, with the National Library of Medicine providing extensive resources for CRC research.

Get a glance at the market report of share of various segments Request Free Sample

The targeted therapy segment was valued at USD 3.18 billion in 2018 and showed a gradual increase during t

Overview

New York, NY – May 20, 2025 – Global Colorectal Cancer Therapeutics Market size is expected to be worth around US$ 19.8 Billion by 2033 from US$ 12.5 Billion in 2023, growing at a CAGR of 4.7% during the forecast period from 2024 to 2033.

The global colorectal cancer therapeutics market is witnessing steady growth, driven by rising incidence rates, advancements in treatment modalities, and growing public awareness regarding early diagnosis. Colorectal cancer (CRC) is the third most commonly diagnosed cancer worldwide and a leading cause of cancer-related deaths. According to the World Health Organization (WHO), colorectal cancer accounted for over 1.9 million new cases and approximately 935,000 deaths globally in 2020.

The market is experiencing strong momentum due to increasing investments in precision medicine, targeted therapies, and immuno-oncology. Treatments such as chemotherapy, radiation therapy, targeted drugs (e.g., EGFR and VEGF inhibitors), and immune checkpoint inhibitors have improved survival outcomes for CRC patients. In recent years, biologics and combination regimens have shown enhanced efficacy, especially in advanced and metastatic colorectal cancer cases.

North America dominates the global market owing to robust healthcare infrastructure, supportive reimbursement policies, and high screening rates. Meanwhile, the Asia-Pacific region is expected to witness significant growth due to increasing awareness and expanding access to oncology care. Further, research into biomarkers and molecular profiling is enabling the development of personalized therapies. Government initiatives, including cancer screening programs and public health campaigns, are expected to continue supporting market expansion.

Investigator initiated multi-institutional retrospective review of clinical and radiographic outcomes after 90Y resin microsphere radioembolization for metastatic colorectal liver metastases in the USA. The target is for at least 1,000 evaluable patients with 12+ weeks follow up.

BackgroundRegorafenib and trifluridine/tipiracil (FTD/TPI) ± bevacizumab are both indicated for patients diagnosed with metastatic colorectal cancer (mCRC) in the third line or later. However, in the absence of recommendations regarding preferred treatment order, our study aimed to improve the understanding of real-world optimal treatment sequences.MethodsThis retrospective study assessed real-world outcomes and treatment patterns among mCRC patients who initiated sequential regorafenib and FTD/TPI ± bevacizumab between the first line and sixth line from September 2015 to November 2022 in The US Oncology Network. Patient and treatment characteristics were assessed descriptively overall and stratified by treatment order. The Kaplan–Meier methods were used for time-to-event endpoints, including real-world overall survival (rwOS), real-world progression-free survival (rwPFS), and real-world time to next treatment (rwTTNT) following sequence. Endpoints were also evaluated using Cox proportional hazards models.ResultsThis study examined 308 patients initiating sequential regorafenib and FTD/TPI, 156 patients initiating regorafenib first (R-T), and 152 patients initiating FTD/TPI first (T-R). Demographic and clinical characteristics were similar across cohorts. The population was predominantly male and had a mean age of 63 years and colon primary at diagnosis. The median rwOS was numerically longer among the R-T cohort compared to the T-R cohort (12.8 [11.2, 14.1] vs. 10.2 [8.8, 11.9] months). The median rwPFS was similar (3.4 [3.0, 3.6] vs. 3.4 [3.0, 3.7 months) for both the R-T and T-R cohorts. The median rwTTNT following sequence was numerically longer among the R-T cohort compared to the T-R cohort (9.3 [8.4, 10.3] vs. 8.6 [7.8, 9.4] months). Index treatment was not significantly associated with rwOS (Hazard Ratio (HR) = 1.2, p = 0.2), rwPFS (Hazard Ratio (HR) = 0.9, p = 0.4), or rwTTNT (Hazard Ratio (HR) = 1.1, p = 0.6).ConclusionTreatment sequence numerically favored R-T and provided an additional survival benefit of 2.6 months in this cohort, although this was not statistically significant. Providing access to regorafenib and FTD/TPI ± bevacizumab is critical to maximizing patient benefit and optimizing patient care in advanced stages of mCRC.

Various antiangiogenic agents have a modest effect in prolonging overall survival in solid tumours. In colorectal cancer it is clear that there are some patients in whom bevacizumab significantly prolongs survival, but it is not effective in the majority of patients. Biomarker studies using tumour tissue and blood have failed to define a consistent biomarker that correlates with a beneficial effect of bevacizumab on survival. DCE-MRI can detect changes in tumour blood flow which, in early phase drug studies, correlated with subsequent tumour responses, but is too expensive and time consuming to be used in larger scale trials. DCE-US is a promising biomarker for use in this group of patients with antiangiogenic agents, as detailed above. The investigators wish to use this technique as a predictive biomarker for any effects Aflibercept has on OS and PFS in patients with metastatic colorectal cancer refractory to standard treatment.

Background: * Colorectal cancer (CRC) is a major public health problem in the U.S. and worldwide, and 5-year survival with widespread metastatic disease is less than 5%. * Expression of epidermal growth factor receptor (EGFR) or up-regulation of the gene occurs in the majority of CRC cases (60-80%). * Therapies targeting EGFR, like cetuximab, have shown activity in the treatment of solid tumors like CRC. * Cetuximab is FDA (Food and Drug Administration) approved for the treatment of EGFR-expressing CRC, but clinical responses to cetuximab are seen in only 10% of EGFR-expressing CRC. * One possible mechanism of resistance to cetuximab could be KRAS (Kirsten rat sarcoma) mutations. * Another major pathway implicated in colon carcinogenesis is the vascular endothelial growth factor (VEGF) pathway, which is involved in angiogenesis and is a validated target for therapy in CRC. * BAY 43-9006 is both a Raf kinase inhibitor and an inhibitor of VEGF receptor (VEGFR2) tyrosine kinase. * We hypothesize that the combined inhibition of EGFR, VEGFR2, and the Ras-(rapidly accelerated fibrosarcoma) Raf pathway will demonstrate promising clinical activity in CRC. Furthermore, in patients with mutant KRAS, combination of cetuximab with a drug that inhibits Raf kinase and acts downstream of Ras mutations, could restore tumor sensitivity to cetuximab. Objectives: * To determine the rate of response (complete response (CR) + partial response (PR) + stable disease (SD) for 4 months) and toxicity profile of combination of BAY 43-9006 and cetuximab in previously treated EGFR-expressing metastatic CRC in patients with mutant KRAS. * To evaluate BAY 43-9006 pharmacokinetics & pharmacogenomics (CYP3A4/5 (cytochrome P450 3A4/5)). * To evaluate for this combination treatment pharmacodynamics, effect on tumor vascularity and effect on angiogenic cytokines. Eligibility: * Adults with histologically or cytologically documented, measurable, EGFR-expressing metastatic CRC, which has recurred or progressed following at least one prior 5FU (Fluorouracil)-based combination chemotherapy regimen administered for the treatment of metastatic disease. * Patients must be KRAS mutation-positive. Design: * BAY 43-9006 will be administered 400 mg by mouth twice daily * Cetuximab will be administered as 400 mg/m^2 loading dose (week 1) followed by 250 mg/m^2 IV (intravenous) weekly. * If procedure may be performed safely, tumor biopsy will be obtained prior to treatment and after 4 weeks of treatment. * Optional positron emission tomography (PET)/computerized tomography (CT) imaging with 89Zr-labeled, EGFR-targeting antibody panitumumab may be performed to evaluate radiation dosimetry, safety, and tumor distribution prior to and following treatment with study agents. * Patients will be evaluated for response every 8 weeks using the RECIST (Response Evaluation Criteria in Solid Tumors) criteria. * This trial uses a phase II optimal design targeting a response rate as defined above of 20% in patients with mutant KRAS. Up to 49 patients may be treated.

These are peer-reviewed supplementary materials for the article 'Adverse event costs of systemic therapies for metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin and irinotecan-based chemotherapy and biologics in the US' published in the Journal of Comparative Effectiveness Research.Supplementary Table 1: Summary of clinical trial study characteristics.Supplementary Table 2: Summary of patient baseline characteristics from clinical trials.Supplementary Table 3: Detailed unit cost information for the Commercial perspective.Supplementary Table 4: Detailed unit cost information for the Medicare perspective.Aim: The objective of this study was to compare adverse event (AE) management costs for fruquintinib, regorafenib, trifluridine/tipiracil (T/T) and trifluridine/tipiracil+bevacizumab (T/T+bev) for patients with metastatic colorectal cancer (mCRC) previously treated with at least two prior lines of therapy from the US commercial and Medicare payer perspectives. Materials & methods: A cost-consequence model was developed to calculate the per-patient and per-patient-per-month (PPPM) AE costs using rates of grade 3/4 AEs with incidence ≥5% in clinical trials, event-specific management costs and duration treatment. Anchored comparisons of AE costs were calculated using a difference-in-differences approach with best supportive care (BSC) as a common reference. AE rates and treatment duration were obtained from clinical trials: FRESCO and FRESCO-2 (fruquintinib), RECOURSE (T/T), CORRECT (regorafenib) and SUNLIGHT (T/T, T/T+bev). AE management costs for the commercial and Medicare perspectives were obtained from publicly available sources. Results: From the commercial perspective, the AE costs (presented as perpatient, PPPM) were: $4015, $1091 for fruquintinib (FRESCO); $4253, $1390 for fruquintinib (FRESCO-2); $17,110, $11,104 for T/T (RECOURSE); $9851, $4691 for T/T (SUNLIGHT); $8199, $4823 for regorafenib; and $11,620, $2324 for T/T+bev. These results were consistent in anchored comparisons: the difference in-difference for fruquintinib based on FRESCO was -$1929 versus regorafenib and -$11,427 versus T/T; for fruquintinib based on FRESCO-2 was -$2257 versus regorafenib and -$11,756 versus T/T. Across all analyses, results were consistent from theMedicare perspective. Conclusion: Fruquintinib was associated with lower AE management costs compared with regorafenib, T/T and T/T+bev for patients with previously treated mCRC. This evidence has direct implications for treatment, formulary and pathways decision-making in this patient population.

The market is segmented based on product type, end-user, and region. The product type segment includes surgery, radiation therapy, chemotherapy, immunotherapy, tumor treating field (TTF) therapy, and others. The end-user segment includes hospitals & clinics and ambulatory surgical centers. Recent developments include: July 2019: Amgen, Inc (US) and Allergan plc (Ireland) have announced that MVASI (bevacizumab-awwb), a biosimilar to Avastin (bevacizumab), is now available in the United States (U.S.). This launch will result in an increase in the product's sales in the region., June 2019: The US Food and Drug Administration (FDA) has approved Zirabev, a Pfizer biosimilar of Avastin for the treatment of metastatic or recurrent non-small cell lung cancer (NSCLC), metastatic colorectal cancer, metastatic renal cell carcinoma, recurrent glioblastoma multiforme, and metastatic cervical cancer.. Notable trends are: The increasing incidence of glioblastoma multiforme globally to boost the market growth..

Snapshot img

CTLA4 Inhibitors Market Size 2025-2029

The CTLA4 inhibitors market size is forecast to increase by USD 3.5 billion, at a CAGR of 19.1% between 2024 and 2029.

The market is characterized by the high target affinity and specificity of CTLA4 inhibitors, making them an attractive therapeutic option in the field of oncology. This market's expansion is further driven by the ongoing research into new indications for CTLA4 inhibitors, broadening their potential applications and patient base. However, the lack of approved CTLA4 therapies presents a significant challenge for market growth. Despite this hurdle, companies can capitalize on the market's potential by investing in clinical trials and collaborations to bring new CTLA4 inhibitor therapies to market.
Additionally, focusing on addressing the unique challenges associated with CTLA4 inhibitor development, such as toxicity and resistance, can help companies differentiate themselves and gain a competitive edge. Overall, the market holds immense promise, with the potential to revolutionize cancer treatment through targeted immunotherapy. Companies that effectively navigate the challenges and seize opportunities in this market will be well-positioned for success.

What will be the Size of the CTLA4 Inhibitors Market during the forecast period?

Explore in-depth regional segment analysis with market size data - historical 2019-2023 and forecasts 2025-2029 - in the full report.
Request Free Sample

The CTLA-4 inhibitors market continues to evolve, driven by advancements in Cancer Immunotherapy and the ongoing development of new treatment options. Response rates have shown significant improvement in various sectors, with ongoing clinical trials exploring the potential of CTLA-4 inhibitors in combination with other targeted therapies and immune checkpoint inhibitors. The role of drug metabolism in optimizing treatment efficacy and minimizing adverse events is a growing area of focus. Treatment guidelines are continually being updated to reflect the latest research findings, with a greater emphasis on personalized medicine and patient selection based on tumor mutational burden, microsatellite instability, and other biomarkers.

Healthcare economics and market access remain critical considerations, with pricing strategies and intellectual property rights shaping the competitive landscape. Healthcare professionals are increasingly leveraging next-generation sequencing and liquid biopsies to improve disease management and monitor treatment response. Regulatory approval and EMA approval processes are ongoing, with a focus on ensuring the safety and efficacy of new CTLA-4 inhibitors. The supply chain and distribution channels are also evolving to meet the growing demand for these therapies, with a focus on ensuring quality and reliability. Ongoing research into drug interactions and Monoclonal Antibodies is further expanding the potential applications of CTLA-4 inhibitors in precision oncology.

Phase III trials are underway to explore the long-term health outcomes of CTLA-4 inhibitor therapy, including progression-free survival and overall survival. The ongoing unfolding of market activities and evolving patterns underscores the dynamic nature of the CTLA-4 inhibitors market and its continued potential for growth and innovation.

How is this CTLA4 Inhibitors Industry segmented?

The CTLA4 inhibitors industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

Type

  Monotherapy
  Combination therapy


Distribution Channel

  Hospital pharmacies
  Retail pharmacies
  Online pharmacies


Route Of Administration

  Intravenous
  Subcutaneous


Geography

  North America

    US
    Canada


  Europe

    France
    Germany
    Italy
    The Netherlands
    UK


  APAC

    China
    India
    Japan


  Rest of World (ROW)

By Type Insights

The monotherapy segment is estimated to witness significant growth during the forecast period.

CTLA4 inhibitors have gained significant attention in the cancer therapeutics market due to their efficacy in treating specific subtypes of melanomas, non-small cell lung cancer (NSCLC), metastatic colorectal cancer (mCRC), and mesothelioma. These cancers are characterized by the malfunctioning of the CTLA4 protein, making them responsive to targeted therapies such as CTLA4 inhibitors, administered as monotherapy. The US Food and Drug Administration (FDA) approved YERVOY as the first monotherapy for metastatic and unresectable melanoma in 2011, increasing its popularity. Patient advocacy groups have played a crucial role in raising awareness and promoting the use of these therapies. Patent protection ensures that pharmaceutical companies can profitably invest in research and developme

Snapshot img

BRAF Kinase Inhibitors Market Size 2025-2029

The BRAF kinase inhibitors market size is forecast to increase by USD 2.16 billion at a CAGR of 9% between 2024 and 2029.

The market is characterized by the high target affinity and specificity of these inhibitors, making them an attractive option for treating various types of cancers. The expansion of research areas in BRAF kinase inhibitors, particularly in the development of novel formulations and combination therapies, presents significant growth opportunities for market participants. However, the availability of substitute therapies poses a challenge to market growth. Monoclonal antibodies and cell therapy, including CAR T-cell therapy, are also making an impact. These alternatives, including targeted therapies and chemotherapies, offer competitive treatment options for patients, potentially limiting the market's expansion.
Companies seeking to capitalize on the market's potential must focus on enhancing the efficacy and safety of their BRAF Kinase Inhibitors while addressing the challenges posed by substitute therapies. Strategic collaborations, product differentiation, and targeted marketing efforts can help companies navigate this competitive landscape and maintain a strong market position. Additionally, supply chain inconsistencies temper growth potential, as disruptions can lead to shortages and price fluctuations.

What will be the Size of the BRAF Kinase Inhibitors Market during the forecast period?

Explore in-depth regional segment analysis with market size data - historical 2019-2023 and forecasts 2025-2029 - in the full report.
Request Free Sample

In the dynamic world of oncology, the market for BRAF kinase inhibitors continues to evolve, driven by physician expertise, genomic advancements, and international collaboration. Colorectal cancer, fueled by the unchecked growth of cancer cells expressing the BRAF kinase enzyme, remains a significant focus. Cutting-edge technology, including the use of Teccentriq (atezolizumab) and Cotellic (cobimetinib), is transforming treatment approaches.
Amidst these developments, the novel coronavirus and remote work environments present new challenges, necessitating continued innovation and flexibility in the delivery of personalized medicine. Medical tourism and patient advocacy efforts are also shaping the landscape, providing clinical trial opportunities for those seeking innovative solutions.

How is this BRAF Kinase Inhibitors Industry segmented?

The BRAF kinase inhibitors industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

Product

  Dabrafenib
  Sorafenib
  Vemurafenib
  Encorafenib


Distribution Channel

  Hospital pharmacies
  Retail pharmacies
  Online pharmacies


Indication

  Metastatic melanoma
  Metastatic lung cancer
  Others


Geography

  North America

    US
    Canada


  Europe

    France
    Germany
    Italy
    UK


  APAC

    China
    India
    Japan


  South America

    Brazil


  Rest of World (ROW)

By Product Insights

The dabrafenib segment is estimated to witness significant growth during the forecast period. Dabrafenib, an orally administered BRAF kinase inhibitor marketed under the brand name TAFINLAR, targets cancers with mutated BRAF genes. This drug inhibits the associated BRAF enzyme, contributing to the regulation of cell growth. Clinical trials have demonstrated dabrafenib's efficacy and manageable safety profile in treating BRAF(V600)-mutated metastatic melanoma, as well as various other mutated forms of BRAF kinases, such as V600E, V600K, and V600D. The market growth is significantly influenced by the high prevalence of lung and thyroid cancers, particularly in the context of dabrafenib's unique approval for treating NSCLC with the BRAF V600E mutation. In oncology centers, drug resistance and personalized medicine have led to an increased focus on targeted therapies, such as BRAF kinase inhibitors, in cancer treatment.

Hospital pharmacies and online pharmacies play crucial roles in ensuring the availability of these essential medications. The MAPK signaling pathway is a critical player in abnormal cell growth, making BRAF kinase inhibitors a valuable tool in cancer therapy. Combination therapies, including dabrafenib in combination with trametinib, have shown promise in treating metastatic lung cancer and colorectal cancer. However, liver toxicity remains a concern, necessitating ongoing diagnostic capabilities and careful monitoring. Healthcare awareness and the increasing prevalence of metastatic cancers continue to fuel the demand for effective treatments, such as BRAF kinase inhibitors.

Download Free Sample Report

The Dabrafenib segment was valued at USD 1.45 billion in

ObjectivesWe aimed to compare the economic value of chemotherapy plus anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibody (mAb) against chemotherapy with bevacizumab (Bev, an anti-vascular endothelial growth factor mAb) as first-line treatment in KRAS wild-type (WT), pan-RAS WT and pan-RAS WT left-sided metastatic colorectal cancer (mCRC) patients from the Hong Kong societal perspective.Materials and MethodsWe developed Markov models and 10-year horizon to estimate costs, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratio (ICER) of chemotherapy plus anti-EGFR therapy against chemotherapy plus Bev in KRAS WT, pan-RAS WT, and pan-RAS WT left-sided mCRC. We considered two times of the local gross domestic product per capita (GDPpc) as the willingness-to-pay (WTP) threshold (2× GDPpc; US$97,832).ResultsAdding anti-EGFR mAb to chemotherapy provides additional 0.24 (95% confidence interval [CI] 0.19–0.29), 0.32 (95% CI 0.27–0.37), and 0.57 (95% CI 0.49–0.63) QALY compared to adding Bev in KRAS WT, pan-RAS WT, and left-sided pan-RAS WT mCRC populations respectively. The corresponding ICER is US$106,847 (95% CI 87,806–134,523), US$88,565 (95% CI 75,678–105,871), US$76,537 (95% CI 67,794–87,917) per QALY gained, respectively.ConclusionsAnti-EGFR therapy is more cost-effective than Bev as a first-line targeted therapy in left-sided pan-RAS WT and pan-RAS WT, with ICER

Direct quarterly estimated costs for each health state evaluated, in US dollars ($).